Copertina

Editorial: High Baseline ALT Level Confers Risk of Hepatic Adverse Events During Immune Checkpoint Inhibitors Treatment: A Call for Caution

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Ze‐Hua Zhao, Yu‐Chen Fan
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas
di: Yi‐Ping Hung, et al.
Pubblicazione: (2024)

Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance
di: Romeo Kuo‐Cheng Wu, et al.
Pubblicazione: (2025)

Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance. Authors' Reply
di: Terry Cheuk‐Fung Yip, et al.
Pubblicazione: (2025)

Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation—Current Evidence and Future Directions
di: Mohammad Saeid Rezaee‐Zavareh, et al.
Pubblicazione: (2026)

Editorial: Steroid‐Induced Diabetes in Autoimmune Hepatitis—A Call for Treatment Optimization
di: Pranab M. Barman
Pubblicazione: (2026)

Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation—Current Evidence and Future Directions. Authors' reply
di: L. Aceituno, et al.
Pubblicazione: (2026)

Editorial: Steroid‐Induced Diabetes in Autoimmune Hepatitis—A Call for Treatment Optimisation. Authors' Reply
di: Sarah Flatley
Pubblicazione: (2026)

Coronary Artery Disease and Major Adverse Cardiovascular Events in People With Hepatic Steatosis at Low Atherosclerotic Cardiovascular Disease Risk
di: Julia Karady, et al.
Pubblicazione: (2024)

Editorial: Checkpoint Inhibitor‐Induced Liver Injury—Time to Abandon CTCAE?
di: Kelly Torosian, et al.
Pubblicazione: (2024)

Meta‐Analysis: High anti‐ HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment
di: Shiva Poola, et al.
Pubblicazione: (2025)

Baseline HDV ‐ RNA Levels Could Stratify Clinical Risk Before, But Not After, Cirrhosis in Chronic Hepatitis D: A Multicentre European Study
di: Adriana Palom, et al.
Pubblicazione: (2026)

Letter on ‘Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China’—Authors' Reply
di: Ning Yu, et al.
Pubblicazione: (2025)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors
di: Stefan Mauss
Pubblicazione: (2025)

Determining optimal ALT cut‐off values for predicting significant hepatic histological changes in patients with normal ALT in the grey zone of chronic hepatitis B virus infection
di: Na‐Ling Kang, et al.
Pubblicazione: (2024)

Editorial: Ultralow HBsAg Levels and the Prediction of Cure in Chronic Hepatitis B—Authors' Reply
di: Jian Wang, et al.
Pubblicazione: (2025)

Editorial: Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection—Authors' Reply
di: Yu‐Ping Chang, et al.
Pubblicazione: (2025)

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice
di: Basile Njei, et al.
Pubblicazione: (2024)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors—Authors' Reply
di: Ying‐Nan Tsai, et al.
Pubblicazione: (2025)

Editorial: Residual HCC Risk After Hepatitis C Cure—Can Polygenic Risk Scores Refine Surveillance? Authors' Reply
di: Yu‐Sheng Lin, et al.
Pubblicazione: (2026)

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice. Authors' reply
di: Eunice X. X. Tan, et al.
Pubblicazione: (2024)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease
di: Cong Dai, et al.
Pubblicazione: (2024)

Some Risks of Gastrointestinal Adverse Events Associated With Glucagon‐Like PEPTIDE‐1 Receptor Agonists Are Likely Explained by BMI
di: Benjamin Douglas Liu, et al.
Pubblicazione: (2025)

Increased Risk for Liver Disease in Patients With Chronic Hepatitis B Virus Infection and Low‐Level Viraemia
di: Paul Y. Kwo, et al.
Pubblicazione: (2026)

Editorial: Beyond Viral Eradication—Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C. Authors' Reply
di: Pei‐Chien Tsai, et al.
Pubblicazione: (2026)

Editorial: Beyond Viral Eradication—Scrutinising Outcomes After Hepatitis C Cure
di: Wei‐Fan Hsu, et al.
Pubblicazione: (2025)

Editorial: Low‐Level Viraemia in Chronic Hepatitis B—A Benign State or Missed Opportunity?
di: Miriam T. Levy
Pubblicazione: (2026)

Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication
di: Pei‐Chien Tsai, et al.
Pubblicazione: (2025)

Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy
di: Yu Jun Wong
Pubblicazione: (2025)

Editorial: Beyond Viral Eradication—Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C
di: Shun‐Ichi Wakabayashi, et al.
Pubblicazione: (2026)

Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease—Authors' Reply
di: Jessica D. Lee, et al.
Pubblicazione: (2025)

Liver Fibrosis and the Risk of Coronary Artery Disease, Stent Thrombosis, Restenosis and Adverse Clinical Outcomes
di: Na Tian, et al.
Pubblicazione: (2025)

Upper limit of normal ALT levels in health and metabolic diseases: Pooled analysis of 423,355 individuals with bootstrap modelling
di: Eunice X. Tan, et al.
Pubblicazione: (2024)

Letter on ‘Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China’
di: Dong Hyun Kim, et al.
Pubblicazione: (2025)

Letter on “Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China”
di: Ersel Bilgin, et al.
Pubblicazione: (2025)

Systematic Review: Incidence of Liver‐Related Events in People Living With Hepatitis Delta Virus
di: Laura E. Telep, et al.
Pubblicazione: (2025)

Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection
di: Yu‐Ping Chang, et al.
Pubblicazione: (2025)

Letter: Optimising Prevention of Adverse Events and Antiviral Prophylaxis for HBV ‐Infected HCC Patients Undergoing Immunotherapy
di: Jialing Wang, et al.
Pubblicazione: (2025)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease—Authors' Reply
di: Isabel Carbery, et al.
Pubblicazione: (2024)

Editorial: Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection
di: Nobuharu Tamaki, et al.
Pubblicazione: (2025)

Editorial: HBeAg ‐Positive Chronic Hepatitis B With Low HBsAg Levels—Exploring Clinical Significance of preS2 Deletion Mutations
di: Ying‐Nan Tsai, et al.
Pubblicazione: (2025)